{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:02:07Z","timestamp":1770742927725,"version":"3.49.0"},"reference-count":49,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish MCIN\/AEI\/10.13039\/501100011033","award":["PID2020-113430RB-I00"],"award-info":[{"award-number":["PID2020-113430RB-I00"]}]},{"name":"ERDF A way of making Europe","award":["PID2020-113430RB-I00"],"award-info":[{"award-number":["PID2020-113430RB-I00"]}]},{"name":"European Union","award":["PID2020-113430RB-I00"],"award-info":[{"award-number":["PID2020-113430RB-I00"]}]},{"name":"European Union Next Generation EU\/PRTR","award":["PID2020-113430RB-I00"],"award-info":[{"award-number":["PID2020-113430RB-I00"]}]},{"name":"Regional Catalonian Government","award":["PID2020-113430RB-I00"],"award-info":[{"award-number":["PID2020-113430RB-I00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Background: Cannabidiol (CBD) is a phytocannabinoid with potential in one of the most prevalent syndromes occurring at birth, the hypoxia of the neonate. CBD targets a variety of proteins, cannabinoid CB2 and serotonin 5HT1A receptors included. These two receptors may interact to form heteromers (CB2\u20135HT1A-Hets) that are also a target of CBD. Aims: We aimed to assess whether the expression and function of CB2\u20135HT1A-Hets is affected by CBD in animal models of hypoxia of the neonate and in glucose- and oxygen-deprived neurons. Methods: We developed a quantitation of signal transduction events in a heterologous system and in glucose\/oxygen-deprived neurons. The expression of receptors was assessed by immuno-cyto and -histochemistry and, also, by using the only existing technique to visualize CB2\u20135HT1A-Hets fixed cultured cells and tissue sections (in situ proximity ligation PLA assay). Results: CBD and cannabigerol, which were used for comparative purposes, affected the structure of the heteromer, but in a qualitatively different way; CBD but not CBG increased the affinity of the CB2 and 5HT1A receptor\u2013receptor interaction. Both cannabinoids regulated the effects of CB2 and 5HT1A receptor agonists. CBD was able to revert the upregulation of heteromers occurring when neurons were deprived of oxygen and glucose. CBD significantly reduced the increased expression of the CB2\u20135HT1A-Het in glucose\/oxygen-deprived neurons. Importantly, in brain sections of a hypoxia\/ischemia animal model, administration of CBD led to a significant reduction in the expression of CB2\u20135HT1A-Hets. Conclusions: Benefits of CBD in the hypoxia of the neonate are mediated by acting on CB2\u20135HT1A-Hets and by reducing the aberrant expression of the receptor\u2013receptor complex in hypoxic-ischemic conditions. These results reinforce the potential of CBD for the therapy of the hypoxia of the neonate.<\/jats:p>","DOI":"10.3390\/ijms23179695","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T01:39:19Z","timestamp":1661737159000},"page":"9695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen\/Glucose-Deprived Neurons"],"prefix":"10.3390","volume":"23","author":[{"given":"Jaume","family":"Lillo","sequence":"first","affiliation":[{"name":"CiberNed, Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, 28040 Madrid, Spain"},{"name":"Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Neuroscience, University of Barcelona (NeuroUB), Av Joan XXIII 27-31, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-0495","authenticated-orcid":false,"given":"Iu","family":"Ra\u00efch","sequence":"additional","affiliation":[{"name":"CiberNed, Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, 28040 Madrid, Spain"},{"name":"Institute of Neuroscience, University of Barcelona (NeuroUB), Av Joan XXIII 27-31, 08028 Barcelona, Spain"},{"name":"Molecular Neuropharmacology Laboratory, Department of Biochemistry and Physiology, School of Pharmacy and Food Science, Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Silva","sequence":"additional","affiliation":[{"name":"Biomedical Research Foundation, Hospital Cl\u00ednico San Carlos-IdISSC, 28040 Madrid, Spain"},{"name":"Department of Neonatology, Hospital Cl\u00ednico San Carlos-IdISSC, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Zafra","sequence":"additional","affiliation":[{"name":"Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Lillo","sequence":"additional","affiliation":[{"name":"CiberNed, Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, 28040 Madrid, Spain"},{"name":"Institute of Neuroscience, University of Barcelona (NeuroUB), Av Joan XXIII 27-31, 08028 Barcelona, Spain"},{"name":"Molecular Neuropharmacology Laboratory, Department of Biochemistry and Physiology, School of Pharmacy and Food Science, Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-0626","authenticated-orcid":false,"given":"Carlos","family":"Ferreiro-Vera","sequence":"additional","affiliation":[{"name":"Phytoplant Research S.L.U, Astr\u00f3noma Cecilia Payne Street, Centauro Building, B-1, 14014 C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"S\u00e1nchez de Medina","sequence":"additional","affiliation":[{"name":"Phytoplant Research S.L.U, Astr\u00f3noma Cecilia Payne Street, Centauro Building, B-1, 14014 C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-3545","authenticated-orcid":false,"given":"Jos\u00e9","family":"Mart\u00ednez-Orgado","sequence":"additional","affiliation":[{"name":"Biomedical Research Foundation, Hospital Cl\u00ednico San Carlos-IdISSC, 28040 Madrid, Spain"},{"name":"Department of Neonatology, Hospital Cl\u00ednico San Carlos-IdISSC, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-4919","authenticated-orcid":false,"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[{"name":"CiberNed, Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, 28040 Madrid, Spain"},{"name":"Molecular Neurobiology Laboratory, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain"},{"name":"School of Chemistry, Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Navarro","sequence":"additional","affiliation":[{"name":"CiberNed, Network Center for Neurodegenerative Diseases, National Spanish Health Institute Carlos III, 28040 Madrid, Spain"},{"name":"Institute of Neuroscience, University of Barcelona (NeuroUB), Av Joan XXIII 27-31, 08028 Barcelona, Spain"},{"name":"Molecular Neuropharmacology Laboratory, Department of Biochemistry and Physiology, School of Pharmacy and Food Science, Universitat de Barcelona, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104801","DOI":"10.1016\/j.phrs.2020.104801","article-title":"Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids","volume":"158","author":"Franco","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?","volume":"75","author":"Sagredo","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153426","DOI":"10.1016\/j.phymed.2020.153426","article-title":"\u03949-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in mice","volume":"81","author":"Prados","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","article-title":"Prospects for cannabinoid therapies in basal ganglia disorders","volume":"163","author":"Valdeolivas","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2018.07.031","article-title":"Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism","volume":"157","author":"Morales","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fnins.2016.00406","article-title":"Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders","volume":"10","author":"Navarro","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/PMC.S32171","article-title":"The structure-function relationships of classical cannabinoids: CB1\/CB2 modulation","volume":"8","author":"Bow","year":"2016","journal-title":"Perspect. Medicin. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104940","DOI":"10.1016\/j.phrs.2020.104940","article-title":"Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1\/CB2 heteromer receptors","volume":"159","author":"Navarro","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-45541-9_3","article-title":"Molecular Pharmacology of Phytocannabinoids","volume":"Volume 103","author":"Turner","year":"2017","journal-title":"Progress in the Chemistry of Organic Natural Products"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Varani","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u03949-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.imbio.2009.09.007","article-title":"Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease","volume":"215","author":"Kendall","year":"2010","journal-title":"Immunobiology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"Devi","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1203\/PDR.0b013e3182276b11","article-title":"Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs","volume":"70","author":"Lafuente","year":"2011","journal-title":"Pediatr. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.neuropharm.2012.05.034","article-title":"Cannabidiol administration after hypoxia\u2013ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function","volume":"63","author":"Pazos","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2016.12.017","article-title":"Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke","volume":"116","author":"Vargas","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.STR.0000247921.97794.5e","article-title":"Perinatal ischemic stroke","volume":"38","author":"Nelson","year":"2007","journal-title":"Stroke"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1248\/bpb.32.1538","article-title":"Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism","volume":"32","author":"Hayakawa","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1871527315666160927110305","article-title":"Neuroprotective Effects of Cannabidiol In Hypoxic Ischemic Insult: The Therapeutic Window In Newborn Mice","volume":"16","author":"Mohammed","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nchembio0309-131","article-title":"Building a new conceptual framework for receptor heteromers","volume":"5","author":"Baler","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00702-006-0589-0","article-title":"Intramembrane receptor-receptor interactions: A novel principle in molecular medicine","volume":"114","author":"Fuxe","year":"2007","journal-title":"J. Neural Transm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1038\/sj.bjp.0707571","article-title":"G-protein-coupled receptor heteromers: Function and ligand pharmacology","volume":"153","author":"Franco","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00429-020-02116-4","article-title":"Expression of GPR55 and either cannabinoid CB 1 or CB 2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates","volume":"225","author":"Rico","year":"2020","journal-title":"Brain Struct. Funct."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1007\/s12035-019-1495-4","article-title":"Targeting CB 1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson\u2019s Disease","volume":"56","author":"Aguinaga","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuropharm.2019.02.004","article-title":"Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage","volume":"152","author":"Franco","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","article-title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain","volume":"287","author":"Moreno","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bcp.2018.08.046","article-title":"Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes","volume":"157","author":"Navarro","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/ejn.15134","article-title":"Differential contribution of CB1, CB2, 5-HT1A, and PPAR-\u03b3 receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments","volume":"53","author":"Mori","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/01.STR.0000163083.59201.34","article-title":"Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine1A Receptor-Dependent Mechanism","volume":"36","author":"Mishima","year":"2005","journal-title":"Stroke"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1021\/acs.jmedchem.6b00397","article-title":"Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis","volume":"59","author":"Morales","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15839","DOI":"10.1002\/chem.202003389","article-title":"Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor","volume":"26","author":"Morales","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1021\/acs.jmedchem.1c00561","article-title":"Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2 Receptor Derived from the Natural Product Cannabidiol","volume":"64","author":"Navarro","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fphar.2018.00632","article-title":"Cannabigerol action at cannabinoid CB1 and CB2 receptors and at CB1-CB2 heteroreceptor complexes","volume":"9","author":"Navarro","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00223359","article-title":"Biochemical characterization of the beta-adrenergic receptor of the frog erythrocyte","volume":"28","author":"Caron","year":"1979","journal-title":"Mol. Cell. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002130050346","article-title":"(-)Alprenolol potentiates the disrupting effects of dizocilpine on sensorimotor function in the rat","volume":"132","author":"Zhang","year":"1997","journal-title":"Psychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phrs.2014.02.002","article-title":"Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice","volume":"81","author":"Bertoni","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nmeth.1229","article-title":"Detection of heteromerization of more than two proteins by sequential BRET-FRET","volume":"5","author":"Carriba","year":"2008","journal-title":"Nat. Methods"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnmol.2012.00053","article-title":"NCS-1 associates with adenosine A 2A receptors and modulates receptor function","volume":"5","author":"Navarro","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"36762","DOI":"10.1074\/jbc.M111.280339","article-title":"Post-translational membrane insertion of tail-anchored transmembrane EF-hand Ca2+sensor calneurons requires the TRC40\/Asna1 protein chaperone","volume":"286","author":"Hradsky","year":"2011","journal-title":"J. Biol. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:16:01Z","timestamp":1760141761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":49,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms23179695"],"URL":"https:\/\/doi.org\/10.3390\/ijms23179695","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}